Sophie Golding
- Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations 14
- Lung Cancer Diagnosis and Treatment 3
- Oncology top 1%
- Lung Cancer Research Studies 6
- Colorectal Cancer Treatments and Studies 5
- Pancreatic and Hepatic Oncology Research 2
- Cancer Treatment and Pharmacology 2
- Cancer Research top 2%
- Cancer Genomics and Diagnostics 4
- Genetics top 5%
- Molecular Biology top 10%
- Cancer therapeutics and mechanisms 2
Sophie Golding
19 papers receiving 3.1k citations
Hit Papers
Peers
Comparison fields: 5 of 101
- Pulmonary and Respiratory Medicine 2.6k
- Oncology 1.9k
- Cancer Research 772
- Genetics 207
- Molecular Biology 1.0k
Countries citing papers authored by Sophie Golding
This map shows the geographic impact of Sophie Golding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sophie Golding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sophie Golding more than expected).
Fields of papers citing papers by Sophie Golding
This network shows the impact of papers produced by Sophie Golding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sophie Golding. The network helps show where Sophie Golding may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Sophie Golding, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 5 | |
| 2 | 2018 | 48 | |
| 3 | 2017 | 10 | |
| 4 | 2017 | 65 | |
| 5 | 2017 | 33 | |
| 6 | Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancerbreakdown → | 2017 | 1619 |
| 7 | 2017 | 24 | |
| 8 | 2017 | 5 | |
| 9 | 2017 | 5 | |
| 10 | 2017 | 18 | |
| 11 | 2017 | 22 | |
| 12 | 2016 | 3 | |
| 13 | 2015 | 24 | |
| 14 | 2015 | 13 | |
| 15 | 2015 | 2 | |
| 16 | Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 studybreakdown → | 2014 | 538 |
| 17 | 2013 | 1 | |
| 18 | Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survivalbreakdown → | 2010 | 632 |
| 19 | 2003 | 65 |
About Sophie Golding
Sophie Golding is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Physiology and Hepatology, having authored 19 papers that have together received 3.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Research Studies (6 papers), Colorectal Cancer Treatments and Studies (5 papers), Cancer Genomics and Diagnostics (4 papers), Lung Cancer Diagnosis and Treatment (3 papers), Pancreatic and Hepatic Oncology Research (2 papers), Cancer therapeutics and mechanisms (2 papers) and Cancer Treatment and Pharmacology (2 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (2.6k citations), Oncology (1.9k citations), Cancer Research (772 citations), Genetics (207 citations) and Molecular Biology (1.0k citations). Sophie Golding has collaborated with scholars based in Switzerland, United States and France. Frequent co-authors include Peter N. Morcos, Sai‐Hong Ignatius Ou, Shirish M. Gadgeel, Ali Zeaiter, Bogdana Balas, Alice T. Shaw, Jin Seok Ahn, D. Ross Camidge, Dong‐Wan Kim and Rafał Dziadziuszko. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, BMJ Open, Ecological Engineering and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.